Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹9,433 Cr
verification pending
Revenue YoY
27.4%
reported change
EBITDA
Pending
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Niva Bupa delivered a strong Q4 FY26 with GWP growth of 27.4% to ₹9,433 crore, driven by retail health growth of 35% and market share expansion to 10.4% in Q4. PAT surged 80% to ₹366 crore, with combined ratio improving 160 bps to 101.4% on operating leverage. Management guided for sustained retail industry growth of 17-19% CAGR and expects combined ratio to reach ~99% by FY29, with expense ratio savings offsetting modest loss ratio uptick. Key risks include potential commission cap regulation and competitive pressure from GST-driven volume growth normalization.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects combined ratio to improve to ~99% by FY29, driven by expense ratio savings of 200-250 bps.
- Management reiterated view that retail health industry will grow at 17-19% CAGR over a 5-year horizon.
- Management guided that loss ratio may increase by about 150 bps over time, offset by expense ratio improvements.
Risks flagged
- Regulatory changes could cap commission rates, impacting distribution costs and growth. Management awaits clarity but believes single expense limit is preferable.
- Industry growth may moderate as the GST tailwind fades. Management expects stabilization at 17-19% CAGR, but near-term volatility is possible.
- Group health loss ratio was ~60.5% for FY26, and IFRS loss components on onerous contracts could signal underwriting risk.
Key quotes
- Our combined ratio for FY26 improved by 160 basis points to 101.4%.
- Our retail health growth for the same period was in excess of 40%.
- Our model says combined operating ratio should be let's say 99% or so in FY29.
Research modules